Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Hundreds of Fosamax lawsuits versus Merck ordered readied for trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/30/2013 | 10:53pm CEST

A federal judge overseeing consolidated litigation against Merck & Co over jaw injuries allegedly caused by the osteoporosis drug Fosamax has ordered hundreds of cases be dispersed to courts across the country for trial.

The decision by U.S. District Judge John Keenan in Manhattan marks an unusual and potentially costly development for Merck.

Companies often find it easier to reach settlements in mass tort cases that are consolidated before one judge.

"It's a big deal as it changes the cost paradigm for Merck exponentially," said Timothy O'Brien, a partner at Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor and lawyer representing Fosamax plaintiffs.

The judge's order Thursday requires that 200 cases per month be sent to back to courts where they were initially filed, beginning with the oldest ones.

Lainie Keller, a spokeswoman for Merck, said the company "is committed to defending its conduct in regard to Fosamax and has confidence in its defense strategy that has had so much success in the courts."

The cases before Keenan comprised roughly one-fifth of the 5,075 lawsuits pending nationally in federal and state courts related to Fosamax, a one-time blockbuster medication.

Lawsuits alleging that plaintiffs developed osteonecrosis of the jaw from Fosamax were consolidated before Keenan in 2006.

The judge conducted a series of "bellwether" trials, allowing the parties to assess trends and outcomes in similar cases. A series of wins for plaintiffs, for example, can put them in a better position for settlement talks.

The final Fosamax bellwether trial before Keenan ended in February with a $285,000 verdict for plaintiff Rhoda Scheinberg.

Merck lost just one other of the five bellwether trials before Keenan, when a jury in 2010 awarded Florida resident Shirley Boles $8 million, a sum the judge reduced to $1.5 million.

Keenan's order on Friday came after mediation to resolve 370 cases broke down two weeks ago. O'Brien's law firm and another firm represented plaintiffs in those cases.

Another 104 lawsuits brought by another firm could have been added to the talks if a deal on value was reached, O'Brien said.

Lawyers for the plaintiffs had sought to have 300 cases transferred every four months, while Merck sought to have just 100 cases scheduled for discovery over a six-month period.

Merck has benefited from having the litigation consolidated.

Keenan had thrown out 430 cases after he issued an order last November, which Merck had sought, requiring them to put forth expert reports showing scientific proof of their claims.

But in his order Friday, Keenan said Merck's latest proposal would "unnecessarily prolong" the proceedings before him.

Keenan ordered plaintiffs to recommend by October 11 where to sent the first batch of cases.

An order moving so many personal injury cases home at once is rare, O'Brien said. He noted that Merck reached a $4.85 billion settlement with over the painkiller Vioxx in 2007 only after a federal judge threatened a similar order.

"I anticipate Merck will continue talking and seek to resolve the cases," O'Brien said. "The opportunity is there."

The case is In Re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York, No. 06-md-01789.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

By Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
04/22 MERCK : Announces New Phase 2 Data on Investigational Triple Combination Therapy..
04/21 MERCK : Marc J Bern & Partners LLP Files Lawsuits For A Hundred Individuals Agai..
04/21 MERCK : Real-World Observational Study in the U.S. Veterans Affairs System Evalu..
04/20 MERCK : New Findings from Merck & Company in the Area of Animal Science Describe..
04/20 MERCK : Report Summarizes Mass Spectrometry Study Findings from Merck & Company ..
04/20 MERCK : Recent Findings from Merck & Company Provides New Insights into Chromato..
04/20 MERCK : New Nuclear Magnetic Resonance Findings from Merck & Company Described (..
04/20 MERCK : New Findings in Essential Amino Acids Described from Merck & Company (La..
04/20 MERCK : Data on Pharmaceutical and Biomedical Analysis Reported by Researchers a..
04/20 MERCK : Reports from Merck & Company Highlight Recent Findings in Vaccines (Deve..
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 22, 2017
04/21 FDA approves Merck biosimilar for immune-disorder drug Renflexis
04/21 Merck Leads Rivals In Novel Drug Approvals
04/19 BIOLINERX : COMBAT Engagement
04/18 Healthcare Dogs See Medical Care Tops By Yield But Big Pharma Tops By Gains F..
Advertisement
Financials ($)
Sales 2017 39 677 M
EBIT 2017 13 557 M
Net income 2017 7 454 M
Debt 2017 3 973 M
Yield 2017 3,03%
P/E ratio 2017 21,64
P/E ratio 2018 18,25
EV / Sales 2017 4,38x
EV / Sales 2018 4,23x
Capitalization 169 673 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,9 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.5.13%169 673
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
SANOFI8.35%114 121
More Results